5Z‐7‐Oxozaenol attenuates cuprizone‐induced demyelination in mice through microglia polarization regulation
Brain and Behavior · 2024
DOI: 10.1002/brb3.3487 ↗At a glance
Journal article in Brain and Behavior, 2024. Written by Shiyu Chen and 6 co-authors. Institution: Department of Neurology, Zhujiang Hospital, Southern Medical University, Guangzhou, China. Major MEDLINE topics: Cuprizone, Microglia, Demyelinating Diseases, Mice, Inbred C57BL. Cited 2 times so far (Crossref); 40 references. The full text is freely available (open access, CC BY 4.0). Funded by: National Natural Science Foundation of China.
Abstract (original language)
Introduction
Demyelination is a key factor in axonal degeneration and neural loss, leading to disability in multiple sclerosis (MS) patients. Transforming growth factor beta activated kinase 1 (TAK1) is a critical molecule involved in immune and inflammatory signaling pathways. Knockout of microglia TAK1 can inhibit autoimmune inflammation of the brain and spinal cord and improve the outcome of MS. However, it is unclear whether inhibiting TAK1 can alleviate demyelination.
Methods
Eight‐week‐old male c57bl/6j mice were randomly divided into five groups: (a) the control group, (b) the group treated with cuprizone (CPZ) only, (c) the group treated with 5Z‐7‐Oxozaenol (OZ) only, and (d) the group treated with both cuprizone and 15 μg/30 μg OZ. Demyelination in the mice of this study was induced by administration of CPZ (ig) at a daily dose of 400 mg/kg for consecutive 5 weeks. OZ was intraperitoneally administered at mentioned doses twice a week, starting from week 3 after beginning cuprizone treatment. Histology, rotarod test, grasping test, pole test, Western blot, RT‐PCR, and ELISA were used to evaluate corpus callosum demyelination, behavioral impairment, oligodendrocyte differentiation, TAK1 signaling pathway expression, microglia, and related cytokines.
Results
Our results demonstrated that OZ protected against myelin loss and behavior impairment caused by CPZ. Additionally, OZ rescued the loss of oligodendrocytes in CPZ‐induced mice. OZ inhibited the activation of JNK, p65, and p38 pathways, transformed M1 polarized microglia into M2 phenotype, and increased brain‐derived neurotrophic factor (BDNF) expression to attenuate demyelination in CPZ‐treated mice. Furthermore, OZ reduced the expression of proinflammatory cytokines and increases anti‐inflammatory cytokines in CPZ‐treated mice.
Conclusion
These findings suggest that inhibiting TAK1 may be an effective approach for treating demyelinating diseases.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Neurology, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
- Department of General Practice, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
ORCID profiles: Lingli Lu
Funding
- National Natural Science Foundation of China
Cite
APA
Chen, S., Liu, S., Huang, Y., Huang, S., Zhang, W., Xie, H., & Lu, L. (2024). 5Z‐7‐Oxozaenol attenuates cuprizone‐induced demyelination in mice through microglia polarization regulation. Brain and Behavior. https://doi.org/10.1002/brb3.3487
Vancouver
Chen S, Liu S, Huang Y, Huang S, Zhang W, Xie H, et al. 5Z‐7‐Oxozaenol attenuates cuprizone‐induced demyelination in mice through microglia polarization regulation. Brain and Behavior. 2024. doi:10.1002/brb3.3487
BibTeX
@article{Chen2024,
author = {Chen, Shiyu and Liu, Siyao and Huang, Yalun and Huang, Shiwen and Zhang, Wanzhou and Xie, Huifang and Lu, Lingli},
title = {5Z‐7‐Oxozaenol attenuates cuprizone‐induced demyelination in mice through microglia polarization regulation},
journal = {Brain and Behavior},
year = {2024},
doi = {10.1002/brb3.3487}
}
EUVIMED